Sientra

Sientra, Inc. operates as a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. It operates through two reportable segments: Breast Products and miraDry. The Breast Products segment focuses on sales of its breast implants, tissue expanders and scar management products under the brands Sientra, AlloX2, Dermaspan, Softspan and BIOCORNEUM. The miraDry segment focuses on sales of the miraDry System, consisting of a console and a handheld device which uses consumable single-use bioTips. The company was founded by Hani M. Zeini on August 29, 2003 and is headquartered in Santa Barbara, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q3 2024

Siena Holdings, Inc. operates as a holding American company that manages and operates an assisted care facility through its subsidiary. The private company is located in the US and has subsidiaries in the United States.

SANTA BARBARA, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that Company CEO Ron Menezes has been invited to present at the 2022 Virtual Growth Conference, hosted by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.

Sientra to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th – 30th from 9:00 a.m. - 5:00 p.m.

Maxim lowered the price target on Sientra Inc (NASDAQ: SIEN) to $7 from $13 but kept a Buy rating on the stock.  Analyst Anthony Vendetti notes that the Company's Q4 revenue was in-line with its pre-announcement in January, but gross margin was below expectations.

See Why Did Stifel, Maxim Cut Price Target On Sientra After Q4 Earnings

Sientra (SIEN) delivered earnings and revenue surprises of -42.11% and 0.66%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Sientra (SIEN) Reports Q4 Loss, Tops Revenue Estimates

Sientra, Inc. (SIEN) CEO Ron Menezes on Q4 2021 Results - Earnings Call Transcript

Sixth Consecutive Quarter of Record Growth

Sientra Reports Record Plastic Surgery Revenue for Both Fourth Quarter and Full Year 2021

Sientra (SIEN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Sientra (SIEN) This Earnings Season?

SANTA BARBARA, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it will release financial results for the fourth quarter and full year of 2021 after the close of trading on Wednesday, March 23, 2022. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time.

Sientra to Report Fourth Quarter and Full Year 2021 Financial Results on March 23, 2022

SANTA BARBARA, Calif., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that members of management will present at the upcoming H.C. Wainwright Bioconnect Virtual Conference.

Sientra to Present at the H.C. Wainwright Bioconnect Virtual Conference

SANTA BARBARA, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it has entered into exclusive agreements with Kai Aesthetics, Inc., and Paragon Meditech Company for the distribution of Sientra's breast implants in Canada and China, respectively.1

Sientra Selects Leading Distributors for Two Key International Markets In Preparation for Further Expansion and Growth Acceleration

Sientra, Inc. (SIEN) CEO Ron Menezes on Q3 2021 Results - Earnings Call Transcript

Sientra (SIEN) delivered earnings and revenue surprises of -153.85% and 8.40%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Sientra (SIEN) Reports Q3 Loss, Tops Revenue Estimates

Revenue growth of 28% Year Over Year Revenue growth of 28% Year Over Year

Sientra Reports Record Third Quarter 2021 Revenue for Continuing Operations

SANTA BARBARA, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced that members of management are scheduled to participate in three upcoming investor conferences.

Sientra to Participate in Upcoming Investor Conferences

AbbVie

Johnson & Johnson

The FDA is restricting the sale and distribution of breast implants over concerns about the risks of the devices, limiting the products to healthcare providers and facilities that provide information using the "Patient Decision Checklist." Patients must be given a chance to initial and sign the checklist.

FDA Restricts Sale, Approves New Labeling Of Breast Implants

SANTA BARBARA, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced that it will release financial results for the third quarter of 2021 after the close of trading on Wednesday, November 10, 2021. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time.

Sientra to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

Reshaping Lives: Full Circle will provide post-mastectomy reconstructive breast surgery to women in need of assistance

Sientra® And Mission Plasticos Launch Reshaping Lives: Full Circle™ A Philanthropic Initiative For Women Living In Poverty In America

SANTA BARBARA, Calif., Aug. 25, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgery, today announced that a recent independent study out of Stanford University's School of Medicine, published in PRS Global Open, has confirmed that the Sientra® AlloX2® dual port tissue expander enables efficient management of seroma and early targeted intervention in prepectoral breast reconstruction.

New Study Confirms Sientra's AlloX2's Unique Value in Managing Seroma and Infection Post Reconstruction Procedures

Sientra, Inc.'s (SIEN) CEO Ron Menezes on Q2 2021 Results - Earnings Call Transcript

Shares of Sientra (NASDAQ:SIEN) decreased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 52.94% year over year to ($0.32), which missed the estimate of ($0.22).

Sientra: Q2 Earnings Insights

SANTA BARBARA, Calif., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company exclusively focused on plastic surgery, today announced its financial results for the second quarter ended June 30, 2021.

Sientra Reports Record Breast Products Revenue for Second Quarter 2021, Raises Revenue Guidance for Full Year 2021

Sientra (SIEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sientra (SIEN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

SANTA BARBARA, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced that it will release financial results for the second quarter of 2021 after the close of trading on Tuesday, August 10, 2021. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time.

Sientra to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021

SANTA BARBARA, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced the appointment of Dr. Irina Erenburg and Nori Ebersole to its Board of Directors effective July 16, 2021.

Sientra Appoints Two Medical Aesthetics Leaders to its Board of Directors

SANTA BARBARA, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced that Andy Schmidt has been appointed Chief Financial Officer (CFO) effective immediately. As a key member of Sientra's executive leadership team, Mr. Schmidt will lead the Company's financial operations.

Sientra Announces Appointment of Chief Financial Officer

SANTA BARBARA, Calif., June 11, 2021 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced it has closed the previously announced sale of its miraDry business to 1315 Capital, a healthcare growth equity firm investing in commercial stage companies across medical devices, healthcare services, and therapeutics. The transaction was previously described in the Company's Form 8-K filed on May 11, 2021.

News for Sientra Stock (SIEN)